<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195660</url>
  </required_header>
  <id_info>
    <org_study_id>MA-16-12-01</org_study_id>
    <nct_id>NCT03195660</nct_id>
  </id_info>
  <brief_title>Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study</brief_title>
  <acronym>CAT-PEF</acronym>
  <official_title>Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate feasibility of study conduct and that acceptable&#xD;
      adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently&#xD;
      hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the&#xD;
      criteria will receive ASV therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular Improvements with Minute Ventilation-targeted ASV Therapy in Heart Failure&#xD;
      Study (CAT-HF) was a randomized controlled clinical trial in the United States and Germany.&#xD;
      It was designed to evaluate the effect of ASV in hospitalized heart failure (HFrEF and HFpEF)&#xD;
      patients on a global rank endpoint of survival free from CV hospitalization and improvement&#xD;
      in functional capacity measured by 6-minute walk distance. Analysis of the 126 subjects that&#xD;
      were randomized showed a neutral result for the primary endpoint; however, in the&#xD;
      pre-specified analysis of the primary endpoint by LVEF strata, there was a favorable&#xD;
      statistically significant difference in the HFpEF subgroup (p=0.036).&#xD;
&#xD;
      Although the CAT-HF study showed a positive signal in the HFpEF subgroup, these patients&#xD;
      represented a small percentage of the randomized subjects in the study. The current study&#xD;
      aims to show that by applying newer technologies to support adherence, as well as focusing on&#xD;
      the lessons learned in CAT-HF to identify and recruit HFpEF patients, acceptable adherence to&#xD;
      ASV therapy can be achieved in HFpEF patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding for study was withdrawn&#xD;
  </why_stopped>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Actual">November 15, 2017</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-arm, un-blinded, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ASV Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Average hours used per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KCCQ-12</measure>
    <time_frame>3 months</time_frame>
    <description>Change in KCCQ-12 score. Cardiomyopathy Questionnaire (Kansas City) (KCCQ-12) is a short questionnaire to evaluate quality of life in heart failure patients. All scores are scaled from 0-100 where low scares represent very poor health and high scores represent excellent health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>3 months</time_frame>
    <description>Number of hospitalizations per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
    <description>Number of deaths</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>ASV Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASV Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ASV Therapy</intervention_name>
    <description>AirCurve 10 ASV device set up in AutoSet mode</description>
    <arm_group_label>ASV Therapy</arm_group_label>
    <other_name>AirCurve 10 ASV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years or older&#xD;
&#xD;
          2. Patients with heart failure with preserved ejection fraction (HFpEF; LVEF ≥50%)&#xD;
&#xD;
          3. Hospital admission or equivalent (such as ER visit alone or clinic visit alone) and&#xD;
             acute decompensated HF as determined by:&#xD;
&#xD;
               1. Dyspnea at rest or with minimal exertion AND&#xD;
&#xD;
               2. Treatment with at least one dose of IV diuretic or ultrafiltration AND&#xD;
&#xD;
               3. At least two of the following signs and symptoms:&#xD;
&#xD;
             i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest&#xD;
             X-ray iv. Local BNP or NT pro-BNP level: A. No current atrial fibrillation (AFib):&#xD;
             BNP≥100 pg/mL or NT pro- BNP≥300 pg/mL OR B. Current AFib: BNP≥150 pg/mL or NT&#xD;
             pro-BNP≥450 pg/mL&#xD;
&#xD;
          4. Sleep disordered breathing (SDB) documented by screening polygraphy with an AHI≥15&#xD;
             events/hour (e/hr)&#xD;
&#xD;
          5. Patient is able to fully understand study information and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Right-sided heart failure without left-sided failure&#xD;
&#xD;
          2. Current chronic use (within 4 weeks of study entry) of any PAP therapy (eg, CPAP,&#xD;
             APAP, or bi-level) or contraindicated for PAP therapy&#xD;
&#xD;
          3. Sustained systolic blood pressure &lt;80 mmHg at baseline&#xD;
&#xD;
          4. Complex congenital heart disease&#xD;
&#xD;
          5. Constrictive pericarditis&#xD;
&#xD;
          6. Chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the&#xD;
             day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day&#xD;
             or night)&#xD;
&#xD;
          7. Transient ischemic attack (TIA) or Stroke within 3 months prior to study entry&#xD;
&#xD;
          8. Definite clinically evident acute myocardial infarction within 3 months of study entry&#xD;
&#xD;
          9. Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas&#xD;
&#xD;
         10. Moderate or greater valvular heart disease as the primary reason for heart failure&#xD;
&#xD;
         11. Pregnant, or planning to become pregnant during the study period&#xD;
&#xD;
         12. In the opinion of the investigator, the index acute decompensated HF event was due&#xD;
             primarily to uncontrolled AFib with fast ventricular response rate&#xD;
&#xD;
         13. Inability to comply with planned study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher O'Connor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inova Heart and Vascular Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes Center - West Rhine-Westphalia</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2021</results_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adaptive servo-ventilation</keyword>
  <keyword>ASV</keyword>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03195660/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Six participants overall were consented for the study, and baseline data on these participants was collected at the baseline visit. Following on from this, four participants did not meet the entry criteria for the study. Two participants started ASV therapy, but the study was terminated before the follow up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ASV Therapy</title>
          <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>The study was terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Six participants overall were consented for the study, and baseline data on these participants was collected at the baseline visit. Following on from this, four participants did not meet the entry criteria for the study. Two participants started ASV therapy, but the study was terminated before the follow up period.</population>
      <group_list>
        <group group_id="B1">
          <title>ASV Therapy</title>
          <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejection fraction</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="55" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ASV Adherence</title>
        <description>Average hours used per day</description>
        <time_frame>3 months</time_frame>
        <population>The study was terminated prior to the follow-up period</population>
        <group_list>
          <group group_id="O1">
            <title>ASV Therapy</title>
            <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
          </group>
        </group_list>
        <measure>
          <title>ASV Adherence</title>
          <description>Average hours used per day</description>
          <population>The study was terminated prior to the follow-up period</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>KCCQ-12</title>
        <description>Change in KCCQ-12 score. Cardiomyopathy Questionnaire (Kansas City) (KCCQ-12) is a short questionnaire to evaluate quality of life in heart failure patients. All scores are scaled from 0-100 where low scares represent very poor health and high scores represent excellent health.</description>
        <time_frame>3 months</time_frame>
        <population>The study was terminated prior to the follow-up period</population>
        <group_list>
          <group group_id="O1">
            <title>ASV Therapy</title>
            <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ-12</title>
          <description>Change in KCCQ-12 score. Cardiomyopathy Questionnaire (Kansas City) (KCCQ-12) is a short questionnaire to evaluate quality of life in heart failure patients. All scores are scaled from 0-100 where low scares represent very poor health and high scores represent excellent health.</description>
          <population>The study was terminated prior to the follow-up period</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations</title>
        <description>Number of hospitalizations per subject</description>
        <time_frame>3 months</time_frame>
        <population>The study was terminated prior to the follow-up period</population>
        <group_list>
          <group group_id="O1">
            <title>ASV Therapy</title>
            <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <description>Number of hospitalizations per subject</description>
          <population>The study was terminated prior to the follow-up period</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Number of deaths</description>
        <time_frame>3 months</time_frame>
        <population>The study was terminated prior to the follow-up period</population>
        <group_list>
          <group group_id="O1">
            <title>ASV Therapy</title>
            <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Number of deaths</description>
          <population>The study was terminated prior to the follow-up period</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ASV Therapy</title>
          <description>ASV Therapy&#xD;
ASV Therapy: AirCurve 10 ASV device set up in AutoSet mode</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early; results were not analyzed.&#xD;
Six participants overall were consented for the study; four participants did not meet the entry criteria for the study. Two participants started ASV therapy, but the study was terminated before the follow up period.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adam Benjafield</name_or_title>
      <organization>ResMed</organization>
      <phone>+61 466 634 609</phone>
      <email>adam.benjafield@resmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

